Do stimulant medications used for attention-deficit/hyperactivity disorder increase blood pressure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Yes, Stimulant ADHD Medications Do Increase Blood Pressure

Stimulant medications for ADHD consistently increase both blood pressure and heart rate, though the average increases are mild and clinically insignificant for most patients. However, a significant minority (5-15%) experience more substantial elevations that require monitoring 1.

Magnitude of Blood Pressure Changes

Average Population Effects

  • Systolic blood pressure (SBP) increases by 1-4 mmHg on average 1
  • Diastolic blood pressure (DBP) increases by 1-4 mmHg on average 1
  • Heart rate increases by 1-2 beats per minute on average 1

The most recent and comprehensive meta-analysis (2025) found stimulants increase SBP by 1.93 mmHg and DBP by 1.84 mmHg in both children and adults 2. These effects are sustained with longer-term use (≥8 weeks) 2.

Individual Variability

While average increases are small, 5-15% of patients experience more substantial increases in heart rate and blood pressure that reach clinically significant thresholds 1. A 2018 community study found children on stimulants had 12.3 bpm higher heart rate and 3.0 mmHg higher blood pressure compared to non-ADHD children 3.

Medication-Specific Effects

Stimulants (Methylphenidate and Amphetamines)

Both methylphenidate and amphetamines increase blood pressure and pulse through dopamine and norepinephrine reuptake inhibition 1. Blood pressure and pulse must be monitored as parameters under therapy according to evidence-based guidelines 1.

  • Methylphenidate: Increases SBP by 1.81 mmHg and DBP by 2.42 mmHg in children/adolescents 2
  • Amphetamines: Increase SBP by 1.93 mmHg and DBP by 1.93 mmHg in children/adolescents 2
  • Lisdexamfetamine: Similar cardiovascular effects to other stimulants 2

Non-Stimulants Show Different Patterns

  • Atomoxetine: Also increases blood pressure and heart rate, though potentially with fewer growth effects than stimulants 1
  • Guanfacine and Clonidine: Actually decrease blood pressure and heart rate through alpha-2 adrenergic agonism 1

Clinical Implications and Monitoring

Pre-Treatment Evaluation

Before initiating stimulant therapy, obtain:

  • Personal history of cardiac symptoms (palpitations, syncope, chest pain, exercise intolerance) 1
  • Family history of sudden death, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome 1
  • If risk factors present: Obtain ECG and consider cardiology referral 1

Ongoing Monitoring

Clinicians are encouraged to monitor vital signs regularly in patients receiving stimulant treatment due to the subset experiencing larger increases 1. Blood pressure and pulse should be checked at follow-up visits 1.

Safety Context

Serious Cardiovascular Events Are Rare

Stimulant medications have not been shown to increase the risk of sudden cardiac death beyond background rates in children not receiving stimulants 1. The risk of serious cardiovascular events is extremely low 1.

Long-Term Considerations

While short-term increases are well-documented, the long-term cardiovascular implications remain unclear and require further investigation 3, 4, 5. Since elevated blood pressure and heart rate are risk factors for cardiovascular morbidity in adult life, continued monitoring is warranted 6.

Withdrawal Considerations

Patients taking stimulants are more likely to withdraw from treatment due to adverse effects (risk ratio 2.69) compared to placebo, with an absolute risk increase of 4.3% 7.

Common Pitfalls to Avoid

  • Don't assume all patients have the same response: While average increases are small, 5-15% have clinically significant elevations 1
  • Don't neglect baseline cardiovascular assessment: Family and personal cardiac history must be obtained before starting therapy 1
  • Don't forget that children with ADHD not on medication show no blood pressure differences: The effect is medication-related, not disease-related 3
  • Don't overlook non-stimulant alternatives: For patients with cardiovascular concerns, guanfacine or clonidine may actually lower blood pressure 1

Related Questions

How should I initiate Attention‑deficit/hyperactivity disorder pharmacotherapy and monitor cardiovascular risk in a patient without uncontrolled hypertension or significant cardiac disease?
Is elevated diastolic blood pressure concerning in a patient taking Concerta (methylphenidate)?
In a 16‑year‑old adolescent on a psychostimulant (e.g., methylphenidate or amphetamine) with blood pressure at the 97th percentile for age, sex, and height, can the stimulant be continued?
In a 26‑year‑old woman with ADHD treated with dextroamphetamine (10 mg as needed) and lisdexamfetamine (20 mg daily), also on isotretinoin and escitalopram, who has new‑onset elevated blood pressure, nightly sweats, mild proteinuria/microalbuminuria, low free thyroxine with normal thyroid‑stimulating hormone and otherwise normal labs, what is the most likely cause of her hypertension and what is the next step in management?
What are the uses, dosing, and precautions for dextroamphetamine in patients with attention deficit hyperactivity disorder (ADHD) or narcolepsy, particularly those with a history of cardiovascular disease or high blood pressure?
How should a dialysis patient with a serum sodium of 132 mmol/L be evaluated and managed?
What are the red‑flag features for torticollis that require urgent evaluation?
What is the recommended treatment for urinary tract infection in an inpatient setting?
Do the MRI and X‑ray findings of mild spondylosis, facet arthropathy, disc bulges, and mild central canal stenosis at L4‑L5 explain the chronic low‑back pain in a 27‑year‑old obese female, and what underlying disease processes could cause such early degenerative changes?
How should a patient receiving a continuous intravenous infusion of regular human insulin be transitioned to subcutaneous insulin glargine with pre‑meal rapid‑acting insulin boluses?
In a patient with an elevated urea level of 190 mg/dL, a CRP of 8.5 mg/L, foot cellulitis improving on flucloxacillin, and gout treatment that has not worked, does this indicate osteomyelitis or merely cellulitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.